Tiziana Life Sciences is trading 7.62% up at $1.13 after the last patient began dosing in its Phase 2 intranasal foralumab trial for early/mild Alzheimer’s disease. - The company announced the milestone on October 16; it completes enrollment and begins dosing for all participants. - Topline data are expected in Q1 2027. - The gain comes against a 3.65% pre-market decline in biotech stocks.